Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Alkermes, Inc.
Alkermes Receives Notice from Eli Lilly Terminating Inhaled Insulin Program
March 28th, 2008
Alkermes, Inc. (NASDAQ: ALKS) announced that it has received a letter terminating the development and license agreement between Eli Lilly and Company (Lilly) and Alkermes dated April 1, 2001 thereby terminating the AIR(R) Inhaled Insulin (AIR(R) Insulin) program. The termination will become effective in 90 days. The termination of the agreement also results in the termination of the AIR Insulin supply agreement. Alkermes is evaluating the impact of the termination of the AIR Insulin program on its business and will provide further details following a comprehensive business analysis. Keywords: Alkermes, Inc., Eli Lilly and Company, Pharmaceutical...
Source: Health Business Week (2008-03-28)
|
